Key result
Visceral adiposity predicts worse cardiovascular outcomes, but medicinal weight loss fails to lower CAD risk.
Why the study?
Obesity is a growing global pandemic contributing directly to cardiovascular risk factors and disease, with waist circumference and visceral adiposity as important predictors of outcomes.
Visceral adiposity is a standalone predictor of worse cardiovascular outcomes, though medicinal weight loss has not been shown to lower coronary artery disease risk.
Supports inclusion of visceral adiposity in cardiovascular risk models; leaves open whether medicinal weight loss reduces coronary artery disease incidence.
Most nations' obesity rates have been on the rise since the 1980s, confirming the existence of a worldwide pandemic. Hypertension, dyslipidemia, type 2 diabetes, and sleep problems are incident cardiovascular risk factors that obesity directly contributes to. Even after controlling for other risk factors, obesity increases the likelihood of cardiovascular disease and its death. Waist circumference, rather than body mass index, is a more modern indicator of abdominal obesity as a risk factor for cardiovascular disease. Imaging techniques that assess visceral adiposity and other aspects of body composition have also come a long way. Research looking at the quantification of fat depots (including ectopic fat) lends credence to the idea that increased visceral adiposity is a standalone predictor of worse cardiovascular outcomes. Metabolic syndrome, along with its associated systemic inflammation and endothelial dysfunction, may be ameliorated via changes in lifestyle and, subsequently, weight reduction. On the other hand, medicinal weight loss has not been shown in clinical studies to lower risks of coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2023) conducted a review in Obesity. Obesity vs. Non-obese was evaluated. Obesity and increased visceral adiposity are standalone predictors of worse cardiovascular outcomes, though medicinal weight loss has not been shown to lower coronary artery disease risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: